ARST1431: A Randomized Phase 3 Study of Vincristine Dactinomycin Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI Torisel NSC# 683864 IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma

Brief description of study

If you or your child have been diagnosed with rhabdomyosarcoma (RMS) a type of cancer that occurs in the soft tissues of the body like the muscles, you or your child may qualify to participate in a study evaluating an experimental drug called temsirolimus when added to VAC/VI therapy. The goal of this phase 3 study is to compare the effects, good and/or bad, of a new combination of chemotherapy using VAC/VI plus temsirolimus. In addition, this study aims find if adding the drug temsirolimus to VAC/VI therapy will get rid of the cancer better than VAC/VI by itself.


Clinical Study Identifier: s16-01680
ClinicalTrials.gov Identifier: NCT02567435
Principal Investigator: Sharon L Gardner.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.